Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Organ-on-a-Chip & Tissue-on-a-Chip Europe 2019

James Hickman's Biography



James Hickman, Professor, Nanoscience Technology, Chemistry, Biomolecular Science and Electrical Engineering, University of Central Florida; Chief Scientist, Hesperos

James J. Hickman is a founder and current Chief Scientist of Hesperos, located in Orlando, Florida, which is focusing on cell-based systems for drug discovery and toxicity. He is also the Founding Director of the NanoScience Technology Center and a Professor of Nanoscience Technology, Chemistry, Biomolecular Science, Material Science and Electrical Engineering at the University of Central Florida. Previously, he held the position of the Hunter Endowed Chair in the Bioengineering Department at Clemson University. Dr. Hickman has a Ph.D. from the Massachusetts Institute of Technology in Chemistry. For the past twenty-five years, he has been studying the interaction of biological species with modified surfaces, first in industry and in the latter years in academia. While in industry he established one of the first bioelectronics labs in the country that focused on cell-based sensors and their integration with electronic devices and MEMS devices. He is interested in creating hybrid systems for biosensor and biological computation applications and the creation of functional in vitro systems for human body-on-a-chip applications. He has worked at NSF and DARPA in the area of biological computation. He is a Fellow of both the American Institute of Medical and Biomedical Engineers (AIMBE) (2004) and the American Vacuum Society (AVS) (2007). He was a Board Member for AIMBE from 2009-2013 and Co-Chaired 6 AIMBE/NIH Workshops on “Validation and Qualification of New In Vitro Tools and Models for The Pre-clinical Drug Discovery Process” held at the NIH Campus, Bethesda, MD (2012 – 2017). Dr. Hickman along with Dr. Michael Shuler, won the Lush Prize, in the Science Category, which Supports Animal Free Testing in 2015. He has 135 publications and 20 book chapters, in addition to 22 issued patents out of 44 total patent applications.

James Hickman Image

Human-on-a-Chip Systems For Use in Efficacy and Toxicological Investigations For Applications in Neurological Diseases

Tuesday, 18 June 2019 at 14:15

Add to Calendar ▼2019-06-18 14:15:002019-06-18 15:15:00Europe/LondonHuman-on-a-Chip Systems For Use in Efficacy and Toxicological Investigations For Applications in Neurological DiseasesOrgan-on-a-Chip and Tissue-on-a-Chip Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

One of the primary limitations in drug discovery and toxicology research is the lack of good model systems between the single cell level and animal or human systems. This is especially true for neurodegenerative diseases such as ALS and Alzheimer’s as well as spinal cord injury. In addition, with the banning of animals for toxicology testing in many industries body-on-a-chip systems to replace animals with human mimics is essential for product development and safety testing. Our research focus is on the establishment of functional in vitro systems to address this deficit where we seek to create organs and subsystems to model motor control, muscle function, myelination and cognitive function, as well as cardiac and liver subsystems. The idea is to integrate microsystems fabrication technology and surface modifications with protein and cellular components, for initiating and maintaining self-assembly and growth into biologically, mechanically and electronically interactive functional multi-component systems. Our advances in culturing adult rat, mouse and human mammalian spinal cord, hippocampal neurons, muscle and cardiac cells in a defined serum-free medium, suggest outstanding potential for answering questions related to maturation, aging, neurodegeneration and injury. A specific embodiment of this technology is the creation of a functional human NMJ system to understand ALS. We have investigated four mutations found in ALS patients; SOD1, FUS, TDP43 and C9ORF72. The models have demonstrated variations of the disease phenotype compared to WT for NMJ stability and functional dynamics. Results of these studies will be presented as well as preliminary results for reversal of the deficits. Examples will be given of some of the more advanced human-on-a-chip systems being developed for CNS and PNS disease applications as well as the results of six workshops held at NIH to explore what is needed for validation and qualification of these systems.


Add to Calendar ▼2019-06-18 00:00:002019-06-19 00:00:00Europe/LondonOrgan-on-a-Chip and Tissue-on-a-Chip Europe 2019Organ-on-a-Chip and Tissue-on-a-Chip Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com